share_log

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga ·  Nov 16 05:06

Gainers

  • CERo Therapeutics Hldgs (NASDAQ:CERO) stock increased by 71.0% to $0.32 during Friday's pre-market session. The company's market cap stands at $48.1 million.
  • QT Imaging Holdings (NASDAQ:QTI) shares moved upwards by 18.58% to $0.58. The company's market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago.
  • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 18.02% to $0.77.
  • Alpha Teknova (NASDAQ:TKNO) stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million.
  • Gain Therapeutics (NASDAQ:GANX) shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday.
  • iSpecimen (NASDAQ:ISPC) stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million.

Losers

  • TFF Pharmaceuticals (NASDAQ:TFFP) shares fell 71.9% to $0.45 during Friday's pre-market session. The market value of their outstanding shares is at $1.5 million.
  • Eyenovia (NASDAQ:EYEN) shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago.
  • Akoya Biosciences (NASDAQ:AKYA) stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday.
  • GRI Bio (NASDAQ:GRI) shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday.
  • Tivic Health Systems (NASDAQ:TIVC) shares declined by 17.66% to $0.3. The company's market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday.
  • Carmell (NASDAQ:CTCX) shares decreased by 13.44% to $0.24. The company's market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment